News | Lung Imaging | August 02, 2021

SIR considers image-guided thermal ablation to be an acceptable treatment option for patients with inoperable Stage I NSCLC, those with recurrent NSCLC, as well as patients with metastatic lung disease

SIR considers image-guided thermal ablation to be an acceptable treatment option for patients with inoperable Stage I NSCLC, those with recurrent NSCLC, as well as patients with metastatic lung disease

Getty Images


August 2, 2021 — The Society of Interventional Radiology (SIR) issued a new position statement on percutaneous lung ablation. The position statement was published in the August issue of the Journal of Vascular and Interventional Radiology (JVIR) with an accompanying quality improvement document, which establishes performance thresholds for patient safety.

“Minimally invasive, image-guided thermal ablation offers patients with early stage, non-small-cell lung cancer, recurring lung cancer, and metastatic disease a safe and effective treatment option,” said Mark Baerlocher, M.D., SIR’s standards division councilor and an author of the position statement and quality improvement document.

“The two publications provide physicians with guidance on everything from patient selection to treatment delivery and post-treatment care and follow-up, ensuring high-quality care that improves patients’ lives,” said Baerlocher, an interventional radiologist at the Royal Victoria Hospital, Ontario, Canada.

Lung cancer is the second most common newly diagnosed cancer in the United States, with an estimated 228,000 new cases diagnosed in 2020. It is also the leading cause of cancer-related death.

Interventional radiologists use image-guided thermal ablation to treat primary and secondary lung tumors. Based on the current evidence, the position statement recommends that radiofrequency ablation, cryoablation and microwave ablation are all appropriate forms of image-guided thermal ablation to treat these tumors. The method of ablation should be determined by lesion characteristics and risk mitigation, according to the new document.

“Evidence-based position statements are important means of improving patient outcomes,” said SIR President Mathew S. Johnson, M.D., FSIR, the Gary J. Becker Professor of Radiology Research at Indiana University School of Medicine in Indianapolis. “Future comparative studies on the use of thermal ablation to treat these forms of lung cancer will help improve the evidence base and allow us to make stronger recommendations to the benefit of patients.”

The position statement was developed by a multidisciplinary group of authors including interventional radiology, medical oncology, thoracic surgery and radiation oncology specialists. It is endorsed by the Canadian Association for Interventional Radiology, the Cardiovascular and Interventional Radiological Society of Europe and the Society of Interventional Oncology.

Read the full position statement and quality improvement document on jvir.org.


Related Content

News | Proton Therapy

Sept. 28, 2026 — Penn Medicine and Ion Beam Applications (IBA) have formed Noventra Oncology Alliance, a new joint ...

Time September 28, 2026
arrow
News | ASTRO

Sept. 22, 2026 — Leading experts in radiation therapy from the Abramson Cancer Center (ACC) of the University of ...

Time September 24, 2026
arrow
News | ASTRO

Sept.16, 2026 — For appropriately selected patients with muscle-invasive bladder cancer, preserving the bladder can be a ...

Time September 17, 2026
arrow
News | Radiology Imaging

Sept. 1, 2026 — Leo Cancer Care and GE HealthCare have announced that the two companies intend to work together on GE ...

Time September 11, 2026
arrow
News | ASTRO

Sept. 9, 2026 — The 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, will take place Sept. 26 to 30 ...

Time September 11, 2026
arrow
News | Radiation Oncology

Sept. 2, 2026 — Children with one of the deadliest forms of brain cancer may benefit from an additional course of ...

Time September 03, 2026
arrow
News | Radiation Therapy

Aug. 13, 2026 — An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence ...

Time August 17, 2026
arrow
News | Prostate Cancer

Aug. 13, 2026 — Artera has announced the enrollment of the first patient in its DIRECT-AI registry study, marking the ...

Time August 14, 2026
arrow
News | Innovative Hospitals

July 27, 2026 — Vanderbilt Health and Siemens Healthineers have entered into a multi-year, $87 million Value ...

Time July 28, 2026
arrow
News | ASTRO

July 22, 2026 — The American Society for Radiation Oncology (ASTRO) has announced the 39 members who will receive the ...

Time July 23, 2026
arrow
Subscribe Now